Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1

Interventions

Fulvestrant 10Letrozole 4Alpelisib 4ribociclib 3palbociclib 3Paclitaxel 2NVP-BKM120 2volagidemab 1serabelisib 1sapanisertib 1olaparib 1liposomal doxorubicin 1gedatolisib 1exemestane 1dapagliflozin 1capivasertib 1abemaciclib 1Taxes 1Tamoxifen 1Secretin 1STX-478 1Metformin 1Lomustine 1Leuprolide 1Irinotecan 1Imlunestrant 1Goserelin 1Gemcitabine 1Drug Therapy 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × serabelisib × Breast × Clear all
NCT07558733 2026-04-30

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Faeth Therapeutics

Phase 1/2 Recruiting
32 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡